19:05 , Aug 10, 2018 |  BC Week In Review  |  Company News

Zepatier lands co-exclusive status on Express Scripts 2019 formulary

Express Scripts Holding Co. (NASDAQ:ESRX) announced its 2019 National Preferred Formulary Exclusions , noting that the exclusions were driven not only by the size of the rebate as in years past, but also by lower...
20:46 , Aug 7, 2018 |  BC Extra  |  Company News

Zepatier lands co-exclusive status on Express Scripts 2019 formulary

Express Scripts Holding Co. (NASDAQ:ESRX) announced its 2019 National Preferred Formulary Exclusions , noting that the exclusions were driven not only by the size of the rebate as in years past, but also by lower...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

Tenofovir alafenamide fumarate: Phase III data

Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif.   Product: Tenofovir alafenamide fumarate (TAF)/elvitegravir/cobicistat/emtricitabine (formerly GS-7340/elvitegravir/cobicistat/emtricitabine )   Business: Infectious   Molecular target: NA   Description: Co-formulated single-tablet regimen of tenofovir alafenamide fumarate (TAF), a prodrug...
08:00 , Jan 12, 2015 |  BioCentury  |  Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
08:00 , Nov 3, 2014 |  BioCentury  |  Finance

Shooting F-stars

F-star Alpha Ltd. 's deal with Bristol-Myers Squibb Co. (NYSE:BMY) last week is the first validation of the parent platform company's strategy of speeding returns by packaging assets into corporations for buyer convenience and seller...
07:00 , Jul 28, 2014 |  BioCentury  |  Finance

Staying the course with half a billion

Sofinnova Ventures is sticking with what works for its second life sciences-only fund, which the firm closed last week at $500 million. The fund, the firm's ninth overall, was oversubscribed and was originally targeting $425...
07:00 , Apr 28, 2014 |  BioCentury  |  Finance

Venture hots up

Private biotechs have raised $3.1 billion since the start of the year, double the $1.5 billion raised in the same period last year. At least one investor contacted by BioCentury expects the pace to continue...